Molecular β-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets-Reference-Cited by-同舟云学术

Molecular β-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the ceftazidime-avibactam phase 3 trials (RECAPTURE 1 and 2) for complicated urinary tract infections: Efficacies analysed against susceptible and resistant subsets

Published:2018-08 Issue:2 Volume:52 Page:287-292
ISSN:0924-8579
Container-title:International Journal of Antimicrobial Agents
language:en
Short-container-title:International Journal of Antimicrobial Agents

Author:

Mendes Rodrigo E.,Castanheira Mariana,Woosley Leah N.,Stone Gregory G.,Bradford Patricia A.^ORCID,Flamm Robert K.

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Medicine

Reference20 articles.

1. Systematic review and meta-analysis of antimicrobial treatment effect estimation in complicated urinary tract infection;Singh;Antimicrob Agents Chemother,2013

2. Urinary tract infections: epidemiology, mechanisms of infection and treatment options;Flores-Mireles;Nat Rev Microbiol,2015

3. Antimicrobial-resistant pathogens associated with healthcare-associated infections: Summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014;Weiner;Infect Control Hosp Epidemiol,2016

4. The emerging threat of multidrug-resistant Gram-negative bacteria in urology;Zowawi;Nat Rev Urol,2015

5. Changes in the frequencies of β-lactamase genes among Enterobacteriaceae isolates in U.S. Hospitals, 2012 to 2014: activity of ceftazidime-avibactam tested against β-lactamase-producing isolates;Castanheira;Antimicrob Agents Chemother,2016

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of piperacillin–tazobactam compared with meropenem in treating complicated urinary tract infections including acute pyelonephritis due to extended-spectrum β-lactamase-producing Enterobacteriaceae;Frontiers in Cellular and Infection Microbiology;2023-05-03

2. Assessing clinical cure of empirical piperacillin/tazobactam for ESBL urinary tract infections (ACCEPT—UTI);JAC-Antimicrobial Resistance;2023-05-03

3. What to Do with the New Antibiotics?;Antibiotics;2023-03-27

4. The Use and Effectiveness of Ceftazidime–Avibactam in Real-World Clinical Practice: EZTEAM Study;Infectious Diseases and Therapy;2023-02-10

5. Controversies in the management of ESBL-producing Enterabacterales. Clinical Implications;Revista Española de Quimioterapia;2022-10-24